CRMD Share Price Performance
US$8.02
-2.95 (-26.89%)
52.4% undervalued intrinsic discount
US$16.86
Fair Value
Price US$8.02
AnalystConsensusTarget US$16.86
AnalystLowTarget US$14.00
AnalystHighTarget US$22.00
Fair ValueUS$16.86
Share Pricen/a
CorMedix Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 88 Fair Values set on narratives written by author
CRMD Community Narratives
AN
Fair Value US$16.86 52.4% undervalued intrinsic discount
Acquisition And Pipeline Expansion Will Unlock Healthcare Potential
0users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
AN
Fair Value US$14 42.7% undervalued intrinsic discount
Hospital Anti-Infective Demand Will Face Reimbursement Headwinds Yet Ultimately Support Modest Upside
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$22 63.5% undervalued intrinsic discount
Long Term Infection Prevention Demand Will Drive Expanding Cash Generation And Durable Market Leadership
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Acquisition And Pipeline Expansion Will Unlock Healthcare Potential
Key Takeaways Acquisition and integration efforts diversify revenue streams and improve operational efficiency, supporting stronger earnings and margin growth. Expanded pipeline and portfolio address rising demand in infection control, enhancing market penetration and supporting long-term profitability.Read more
1.1k
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
AN
US$16.86
52.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
22.31% p.a.
Profit Margin
42.03%
Future PE
12.01x
Price in 2029
US$16.03
Hospital Anti-Infective Demand Will Face Reimbursement Headwinds Yet Ultimately Support Modest Upside
Catalysts About CorMedix CorMedix develops and commercializes specialty therapies that prevent and treat life threatening infections in high risk hospital and clinic patients. What are the underlying business or industry changes driving this perspective?Read more
101
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$14
42.7% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
12.31% p.a.
Profit Margin
20.89%
Future PE
26.07x
Price in 2028
US$11.88
Long Term Infection Prevention Demand Will Drive Expanding Cash Generation And Durable Market Leadership
Catalysts About CorMedix CorMedix develops and commercializes differentiated therapies that prevent and treat serious, life-threatening infections in acute care settings. What are the underlying business or industry changes driving this perspective?Read more
35
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$22
63.5% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
38.37% p.a.
Profit Margin
52.62%
Future PE
8.7x
Price in 2028
US$18.67
Trending Discussion
Recently Updated Narratives
AN
CRMD: Updated Revenue Guidance And Investor Day Will Shape Upside Potential
Fair Value: US$16.86 52.4% undervalued intrinsic discount
32 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Hospital Anti-Infective Demand Will Face Reimbursement Headwinds Yet Ultimately Support Modest Upside
Fair Value: US$14 42.7% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Long Term Infection Prevention Demand Will Drive Expanding Cash Generation And Durable Market Leadership
Fair Value: US$22 63.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
CorMedix Inc. Key Details
About CRMD
- Founded
- 2006
- Employees
- 65
- CEO
- WebsiteView website
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
